'Untapped potential for cord blood in disease treatment’ 04-Jul-2022 By Jane Byrne Cell and gene therapy (CGT) researchers have been demonstrating the value of cord blood units as a source material.
Palo Alto CDMO boosts induced pluripotent stem cell manufacturing capacity 17-Mar-2022 By Jane Byrne A California based biotech has tripled its capacity to manufacture GMP grade induced pluripotent stem cells (iPSC) space through the expansion of its contract development and manufacturing (CDMO) facility.